Royal Bank of Canada reiterated their buy rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report released on Wednesday morning. The brokerage currently has a $91.00 target price on the biotechnology company’s stock.
A number of other equities analysts also recently commented on SRPT. JPMorgan Chase & Co. upped their target price on Sarepta Therapeutics from $75.00 to $95.00 and gave the company an overweight rating in a report on Wednesday. Credit Suisse Group upped their target price on Sarepta Therapeutics from $81.00 to $100.00 and gave the company an outperform rating in a report on Tuesday. Piper Jaffray Companies restated an overweight rating and set a $76.12 target price (down previously from $83.00) on shares of Sarepta Therapeutics in a report on Monday. Leerink Swann restated a positive rating and set a $92.00 target price (up previously from $79.00) on shares of Sarepta Therapeutics in a report on Tuesday. Finally, HC Wainwright upped their target price on Sarepta Therapeutics from $75.00 to $92.00 and gave the company a buy rating in a report on Monday. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. Sarepta Therapeutics has a consensus rating of Buy and an average target price of $74.40.
Shares of Sarepta Therapeutics (NASDAQ SRPT) traded up $0.75 during trading on Wednesday, hitting $83.02. The company had a trading volume of 199,600 shares, compared to its average volume of 1,670,651. The company has a debt-to-equity ratio of 0.54, a quick ratio of 12.96 and a current ratio of 13.91. The company has a market capitalization of $5,256.75, a P/E ratio of -102.84 and a beta of 1.52. Sarepta Therapeutics has a one year low of $28.14 and a one year high of $84.11.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Thursday, March 1st. The biotechnology company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.05). The business had revenue of $57.30 million for the quarter, compared to the consensus estimate of $57.33 million. Sarepta Therapeutics had a negative net margin of 32.79% and a negative return on equity of 30.59%. Sarepta Therapeutics’s revenue was up 961.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.71) EPS. equities analysts predict that Sarepta Therapeutics will post -1.18 EPS for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of SRPT. Carillon Tower Advisers Inc. purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter worth $38,720,000. Alyeska Investment Group L.P. purchased a new stake in shares of Sarepta Therapeutics in the third quarter worth $26,011,000. TimesSquare Capital Management LLC purchased a new stake in shares of Sarepta Therapeutics in the third quarter worth $21,521,000. Gilder Gagnon Howe & Co. LLC grew its stake in shares of Sarepta Therapeutics by 63.4% in the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 872,824 shares of the biotechnology company’s stock worth $48,564,000 after acquiring an additional 338,737 shares during the last quarter. Finally, Element Capital Management LLC purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter worth $17,706,000. Institutional investors and hedge funds own 85.14% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Royal Bank of Canada Reaffirms “Buy” Rating for Sarepta Therapeutics (SRPT)” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/03/15/royal-bank-of-canada-reaffirms-buy-rating-for-sarepta-therapeutics-srpt.html.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.